Neuronetics Inc. Common Stock
STIMUnited States
5 filed reports · 271 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 1,011 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 704 | Dec 2025 |
Financial data
271 concepts · 1,715 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial254 concepts · 1,551 facts · Dec 2023 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash and cash equivalents at carrying value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Profit loss13 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Amortization of financing costs12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Depreciation and amortization12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Interest expense borrowings12 · Dec 2023 to Jun 2026
- Interest expense debt12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Operating lease expense12 · Dec 2023 to Jun 2026
- Operating lease lease income12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling and marketing expense (US GAAP)12 · Dec 2023 to Jun 2026
- Allowance for doubtful accounts receivable current11 · Dec 2023 to Jun 2026
- Amortization of deferred sales commissions11 · Dec 2023 to Jun 2026
Segment14 concepts · 136 facts · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)19 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)19 · Dec 2023 to Jun 2026
- Operating income loss19 · Dec 2023 to Jun 2026
- Research and development expense19 · Dec 2023 to Jun 2026
- Revenue18 · Dec 2023 to Jun 2026
- Selling general and administrative expense13 · Dec 2023 to Jun 2026
- Interest expense (US GAAP)4 · Jun 2024 to Sep 2025
- Marketing expense4 · Jun 2024 to Sep 2025
- Other nonoperating income expense4 · Jun 2024 to Sep 2025
- Personnel4 · Jun 2024 to Sep 2025
- Professional fees4 · Jun 2024 to Sep 2025
- Profit loss4 · Jun 2024 to Sep 2025
- Segment reporting other item amount4 · Jun 2024 to Sep 2025
- Gains losses on extinguishment of debt1 · Sep 2024
Product2 concepts · 26 facts · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)13 · Dec 2023 to Jun 2026
- Revenue13 · Dec 2023 to Jun 2026
Geography1 concepts · 2 facts · Jun 2025 to Jun 2026
- Revenue2 · Jun 2025 to Jun 2026
Segments
164 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments4 members · 136 facts
- Medical Device88 · Dec 2023 to Mar 2026
- Clinical Services24 · Dec 2024 to Mar 2026
- Greenbrook12 · Jun 2025 to Jun 2026
- Neurostar12 · Jun 2025 to Jun 2026
Product or service2 members · 26 facts
- Product14 · Dec 2023 to Jun 2026
- Service12 · Dec 2024 to Jun 2026
Statement geographical1 member · 2 facts
- Non Us2 · Jun 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 11, 2026
- FY2026 Q1May 5, 2026
- FY2025 Q4Mar 17, 2026
- FY2025 Q3Nov 4, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.